BiomEdit
BiomEdit is a microbiome biotechnology company developing engineered probiotic products for animal health, with a lead poultry biologic (BE-101/Optavant) targeting necrotic enteritis in broiler chickens and a broader pipeline spanning livestock, aquaculture, and companion animals.
- Company typePrivate
- Founded2022
- HeadquartersFishers, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BiomEdit does
BiomEdit is an animal health biotechnology company that discovers, designs, and develops microbiome-derived products for livestock, poultry, aquaculture, and companion animals. The company operates an integrated platform combining microbiome discovery (high-throughput sequencing and 'omics'), synthetic biology (engineered Lactobacillus reuteri strains enabling localized payload expression), and explainable AI-powered predictive algorithms that improve candidate selection success rates relative to traditional screening methods. Its lead product, BE-101 (to be commercialized under the brand Optavant), is a bacterial-vectored antibody fragment targeting Clostridium perfringens toxins in broiler chickens to prevent necrotic enteritis, with USDA conditional licensure anticipated in Q3 2026 and commercial launch planned for early Q4 2026.
The pipeline extends beyond BE-101 to include BE-102 (Campylobacter jejuni), BE-106 (vectored Eimeria vaccine), BE-01 and BE-02 (livestock gut health), BE-07 (aquaculture probiotics), and BE-105 (feline metabolic disease), supported by 73 patents and 450+ peer-reviewed publications across the team. The business model is B2B enterprise field sales to large commercial poultry and livestock producers, supplemented by a long-term commercial partnership with Nutreco for next-generation ultra-specialty feed additives (Biome-actives). Revenue is not yet generated, and the company is funded through $55.4M in equity ($37M Series A in January 2023, $18.4M Series B in July 2025 led by Anterra Capital) and approximately $6.5M in grants from the Bill and Melinda Gates Foundation and the Bezos Earth Fund.
BiomEdit firmographics
Firmographics- Name
- BiomEdit
- Legal name
- BiomEdit LLC
- Website
- https://biomedit.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BiomEdit is a microbiome biotechnology company developing engineered probiotic products for animal health, with a lead poultry biologic (BE-101/Optavant) targeting necrotic enteritis in broiler chickens and a broader pipeline spanning livestock, aquaculture, and companion animals.
- Ownership category
- akta.pro rank
BiomEdit industry classification
Industry- Product category
- Animal Health Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Other Animal Food Manufacturing (311119), Animal Food Manufacturing (3111)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Agricultural Prod-Livestock & Animal Specialties (200)
- akta.pro primary industry
- Non-Human Microbiome Therapeutics (veterinary/animal microbiome interventions) (HLAAAFAL)
- akta.pro secondary industries
- Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI) (HLAMAHAH), Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials) (AFADALAE), Probiotics, Prebiotics & Synbiotics (AFADAKAC), Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG), Antimicrobials & Anti-infectives (HLAMAEAE)
Keywords
Where BiomEdit is headquartered
LocationHeadquarters
- HQ city
- Fishers
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BiomEdit business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Biologics (Animal Health): Non-antibiotic poultry biologic products (BE-101) sold to commercial broiler producers for disease prevention and performance enhancement. Commercial launch planned for Q4 2026.
- Feed Additives (Foundational Products): Next-generation and ultra-specialty feed additives developed for food animals including livestock and aquaculture, providing novel features that support animal health and growth.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
BiomEdit product offering
Product offeringCore offering
BiomEdit discovers, designs, and develops novel microbiome-derived products for animal health, including engineered probiotic biologics (e.g., BE-101 targeting necrotic enteritis in poultry, marketed as Optavant), next-generation feed additives (Biome-actives), and methane-reduction products for cattle. The company combines microbiome discovery, synthetic biology, and explainable AI to create non-antibiotic solutions for poultry, livestock, aquaculture, and pet health markets.
Differentiator
Problem solved
Functional benefit
Brands
- Optavant: Brand name under which BE-101 non-antibiotic poultry biologic will be commercialized for poultry health.
Products and services
- BE-101 (Optavant)
- BE-102
Quantifiable outcome
- BE-101 demonstrated efficacy in improving feed conversion, weight gain, and reducing mortality caused by necrotic enteritis in broiler chickens
- +1 more outcomes
Companies that use BiomEdit
Customer profileSegments4 records
Ideal customer profiles4 records
BiomEdit technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
BiomEdit partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor.
- AthianminorCollaboration announced October 2023 to develop sustainability protocols in methane-reducing products, as well as AMR and food safety risk reduction projects.
- Indiana Biosciences Research InstituteminorIntegrated drug discovery collaboration announced August 2023.
- AtarrayaminorResearch collaboration announced October 2022 to increase sustainability of shrimp farming and improve global food security.
Scale indicators6 records
Recent moves8 records
Expansion highlights5 records
BiomEdit competitors and assessment
Company assessmentBroad incumbents
- Elanco Animal Health: Global animal health leader and the original parent of BiomEdit's microbiome platform (carved out in 2022). Directly comparable as a broad animal-health incumbent with overlapping interests in livestock, poultry, and pet health; Elanco's existing vaccine and feed-additive portfolios compete with BiomEdit's pipeline.
- Zoetis: Largest pure-play animal health company globally, with biologics, vaccines, and feed-additive products across poultry, livestock, and companion animals. Directly competes with BiomEdit's poultry biologic BE-101 and livestock probiotic programs through established producer relationships.
- Merck Animal Health: Division of Merck & Co. offering vaccines, anti-infectives, and animal health products; competes in the same necrotic enteritis and poultry-health markets as BiomEdit's BE-101. Comparable as a broad incumbent with R&D scale and global distribution.
- Phibro Animal Health: Animal health and nutrition company with significant presence in poultry, swine, and cattle including medicated feed additives and nutritional specialty products; directly competes with BiomEdit's feed-additive and poultry-health offerings.
- Novozymes (Novonesis): Combined Novozymes/Novonesis is a global enzyme and microbial solutions provider with a strong animal-health and feed-additives business; overlaps with BiomEdit's enzyme-based BE-01 livestock product and broader microbial discovery platform.
- dsm-firmenich Animal Nutrition & Health: Major animal nutrition and health player offering vitamins, eubiotics (including probiotics), and performance additives for livestock and aquaculture; broad incumbent competing with BiomEdit across multiple animal segments and especially relevant for methane-reduction work in cattle.
- Cargill Animal Nutrition: Global agribusiness with a large animal nutrition business selling premixes, additives, and feed solutions to livestock and poultry producers; broad incumbent that overlaps with BiomEdit's feed-additive strategy and has the scale to compete on pricing.
Direct peers
- Arm & Hammer Animal and Food Production: Business of Church & Dwight that develops direct-fed microbials, probiotics, and gut-health solutions for livestock and poultry producers. Closely comparable to BiomEdit's feed-additive (Biome-actives) and probiotic pipeline targeting similar producers.
- Chr. Hansen: Global bioscience company with a major animal health and nutrition segment offering probiotic and microbial solutions for poultry, swine, and aquaculture. Directly comparable to BiomEdit's engineered-probiotic platform and DFM feed-additive strategy.
- Kemin Industries: Global ingredient manufacturer specializing in animal nutrition and health, including gut-health, immune, and antibiotic-alternative feed additives for poultry and livestock. Directly comparable to BiomEdit's feed-additive pipeline targeting the same antibiotic-free production trend.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BiomEdit social profiles
Digital presenceBiomEdit financial estimates
Financial estimateRevenue estimate
Valuation estimate
BiomEdit leadership team
Management profileNumber of profiles
Profiles9 records
BiomEdit funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BiomEdit M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BiomEdit
What does BiomEdit do?
BiomEdit discovers, designs, and develops novel microbiome-derived products for animal health, including engineered probiotic biologics (e.g., BE-101 targeting necrotic enteritis in poultry, marketed as Optavant), next-generation feed additives (Biome-actives), and methane-reduction products for cattle. The company combines microbiome discovery, synthetic biology, and explainable AI to create non-antibiotic solutions for poultry, livestock, aquaculture, and pet health markets.
Is BiomEdit a public or private company?
BiomEdit is a private company. It is classified as venture growth investor backed and is currently operating.
When was BiomEdit founded?
BiomEdit was founded in 2022. It employs 11 to 50 people.
Where is BiomEdit based?
BiomEdit is headquartered in Fishers, United States, in the North America region.
How does BiomEdit make money?
Two revenue lines are on record. Biologics (Animal Health) is the primary driver. The others are feed Additives (Foundational Products).
Who are BiomEdit's main competitors?
Broad incumbents on record are Elanco Animal Health, Zoetis, Merck Animal Health, Phibro Animal Health, Novozymes (Novonesis), dsm-firmenich Animal Nutrition & Health and Cargill Animal Nutrition. Direct peers are Arm & Hammer Animal and Food Production, Chr. Hansen and Kemin Industries.
Does BiomEdit have an API?
No public API is recorded for BiomEdit.
What industry is BiomEdit in?
BiomEdit's product category is Animal Health Biologics. Its primary akta.pro industry code is HLAAAFAL, Non-Human Microbiome Therapeutics (veterinary/animal microbiome interventions), with a secondary code of HLAMAHAH, Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI). Its NAICS code is 325414 and its SIC code is 2836.